Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors
AssigneeMemorial Sloan Kettering Cancer Center
InventorsJohannes L. Zakrzewski, Marcel R. m. Van Den Brink, Michel Sadelain
Life of this patent
Estimating the term…
Abstract
The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.
Claims10
A method for treating a human T-cell deficiency in a subject in need thereof, comprising administering to said subject a composition comprising double negative (DN) T-cell precursors from an allogeneic donor, wherein said DN T-cell precursors consist essentially of:
- cells having a DN2 (CD44+CD25+) phenotype or phenotype of an equivalent human DN precursor thereof,
- cells having a DN3 (CD44−CD25+) phenotype or phenotype of an equivalent human DN precursor thereof, or
- cells having a DN2 (CD44+CD25+) phenotype or a phenotype of an equivalent human DN precursor thereof and cells having a DN3 (CD44−CD25+) phenotype or phenotype of an equivalent human DN precursor thereof,
- wherein the major histocompatibility complex (MHC) of said allogeneic donor is not matched to the MHC of said subject, wherein said DN T-cell precursors comprise a nucleic acid sequence which encodes for a chimeric antigen receptor.
Dependencies are inferred from the claim text.